Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Health-related R&D priorities until 2030: Russian experience

Health-related R&D priorities until 2030: Russian experience PurposeThe aim of this paper is to present results of a foresight study on identifying priorities for health-related research and development (R&D) in Russia for the period until 2030.Design/methodology/approachResearch priorities were identified through consistent integrated expert analysis and evaluation of the subject area, i.e. biomedical research preceding development of medical technologies.FindingsKey global and national trends in the biomedical R&D sector and related areas (medicine and health) were identified. According to the experts, the following markets have the best prospects for Russia: regenerative medicine, biodegradable and other biocompatible materials, diagnostic systems, implants, surgical equipment, targeted delivery systems and non-invasive visualisation systems. Entering these markets requires providing support to R&D in the following areas: promising drug candidates, molecular diagnostics, molecular profiling and mechanisms of human diseases, cell technologies (therapies), new materials (biomimetics and other), bioelectronic, bioimaging and biosensors and human genome databases.Practical implicationsRegularly updating research priorities is a necessary prerequisite of successful science and technology development of countries, innovative companies and academic institutions. Allocation of (always limited) financial resources on the basis of such priority-setting exercises’ results is evidence of adherence to scientific planning principles. Combined with monitoring and evaluation tools, priority setting for biomedical R&D must become an integral component of Russia’s innovation policy.Originality/valueThis is a first-ever presentation of Russian experience in setting research priorities for the health-related sphere. Global and national contexts for development of biomedical R&D are described; markets and research areas with the biggest potential for Russian companies are identified. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png foresight Emerald Publishing

Health-related R&D priorities until 2030: Russian experience

foresight , Volume 19 (5): 10 – Sep 11, 2017

Loading next page...
 
/lp/emerald-publishing/health-related-r-d-priorities-until-2030-russian-experience-4N2dZlJ5oa

References (9)

Publisher
Emerald Publishing
Copyright
Copyright © Emerald Group Publishing Limited
ISSN
1463-6689
DOI
10.1108/FS-06-2016-0022
Publisher site
See Article on Publisher Site

Abstract

PurposeThe aim of this paper is to present results of a foresight study on identifying priorities for health-related research and development (R&D) in Russia for the period until 2030.Design/methodology/approachResearch priorities were identified through consistent integrated expert analysis and evaluation of the subject area, i.e. biomedical research preceding development of medical technologies.FindingsKey global and national trends in the biomedical R&D sector and related areas (medicine and health) were identified. According to the experts, the following markets have the best prospects for Russia: regenerative medicine, biodegradable and other biocompatible materials, diagnostic systems, implants, surgical equipment, targeted delivery systems and non-invasive visualisation systems. Entering these markets requires providing support to R&D in the following areas: promising drug candidates, molecular diagnostics, molecular profiling and mechanisms of human diseases, cell technologies (therapies), new materials (biomimetics and other), bioelectronic, bioimaging and biosensors and human genome databases.Practical implicationsRegularly updating research priorities is a necessary prerequisite of successful science and technology development of countries, innovative companies and academic institutions. Allocation of (always limited) financial resources on the basis of such priority-setting exercises’ results is evidence of adherence to scientific planning principles. Combined with monitoring and evaluation tools, priority setting for biomedical R&D must become an integral component of Russia’s innovation policy.Originality/valueThis is a first-ever presentation of Russian experience in setting research priorities for the health-related sphere. Global and national contexts for development of biomedical R&D are described; markets and research areas with the biggest potential for Russian companies are identified.

Journal

foresightEmerald Publishing

Published: Sep 11, 2017

There are no references for this article.